Skip to main content

Gallbladder and Bile Duct Cancer Awareness Month: Improving Screening and Treatment Options With Waqas Haque, MD, MPH, and Matthew Hadfield, DO

In honor of Gallbladder and Bile Duct Cancer Awareness Month this February, Fellows Forum members Dr. Waqas Haque and Dr. Matthew Hadfield sat down for a discussion on the challenges in diagnosis of gallbladder and bile duct cancers and the importance of genetic sequencing for making targeted treatments available for patients.   Waqas Haque, MD, MPH: Hi everybody, thanks for joining our Oncology Data Advisor podcast today. My name is Waqas Haque. I'm a third-year Internal Medicine Resident ...

Continue reading

Exploring Epcoritamab for Relapsed/Refractory Follicular Lymphoma: Dr. Matthew Hadfield, Dr. Alankrita Taneja, Dr. Tahi Ahmadi, and Dr. Jacqueline Nielsen

Recently, Genmab and AbbVie announced updated results of the phase 1/2 EPCORE™ NHL-1 trial of epcoritamab (epco) for patients with R/R follicular lymphoma. In this interview, Dr. Matthew Hadfield and Dr. Alankrita Taneja of the Fellows Forum speak with Dr. Tahi Ahmadi, Chief Medical Officer at Genmab, and Dr. Jacqueline Nielsen, Therapeutic Area Head for Hematology at AbbVie, about the significance of these results, the benefits of epcoritamab's subcutaneous administration, management of adverse events, and the future role of epcoritamab in follicular lymphoma treatment.  

Continue reading

The Rise of Immunotherapy: Considerations to Ensure Optimal Management With Matthew Hadfield, DO

In this Oncology Data Advisor Fellows Forum Interview, Dr. Matthew Hadfield, third-year Hematology/Oncology Fellow at Brown University, shares a comprehensive timeline of the history of immunotherapy and its emerging role in cancer treatment. Additionally, he shares considerations for the differential diagnosis of immunotherapy-related adverse events, timely management for providing optimal efficacy outcomes, and the importance of keeping immunotherapy-related toxicities on the radar for clinicians of all specialties and types of practice.  

Continue reading

Lung Cancer Awareness Month: A Fellows Forum Panel With Waqas Haque, MD, MPH; Samuel Kareff, MD, MPH; and Matthew Hadfield, DO


On the first day of Lung Cancer Awareness Month, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined forces to share recent advances in lung cancer research and ways to raise awareness of this disease for both the public and the health care community throughout the month of November. Hear unique perspectives from Matthew Hadfield, DO, Hematology/Oncology Fellow at Brown University; Waqas Haque, MD, MPH, Internal Medicine Resident at New York University; and Samuel Kareff, MD, MPH, Hematology-Oncology Fellow at the University of Miami. 

Continue reading

World Cancer Research Day With Samuel Kareff, MD, MPH; Maria Badillo, RN; Matthew Hadfield, DO; and Alankrita Taneja, MD

In honor of World Cancer Research Day, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined forces to share their passions for cancer research, discuss the recent and upcoming progress in their respective areas of study, and raise awareness for the tireless efforts being undertaken to advance cancer research.  

Continue reading

Creating Educational Opportunities During Fellowship: Board Exam Prep, Live Meetings, and Beyond With Samuel Kareff, MD, MPH, and Matthew Hadfield, DO

This Fellows Forum episode features Dr. Samuel Kareff and Dr. Matthew Hadfield in a discussion about unique ways to create educational opportunities during Hematology/Oncology Fellowship, including board exam preparation, methods for teaching residents and other fellows, and the value of live and virtual onsite continuing medical education (CME) meetings

Continue reading

The Rise of Immunotherapy: Considerations to Ensure Optimal Management With Matthew Hadfield, DO

In this Oncology Data Advisor Fellows Forum Interview, Dr. Matthew Hadfield, third-year Hematology/Oncology Fellow at Brown University, shares a comprehensive timeline of the history of immunotherapy and its emerging role in cancer treatment. Additionally, he shares considerations for the differential diagnosis of immunotherapy-related adverse events, timely management for providing optimal efficacy outcomes, and the importance of keeping immunotherapy-related toxicities on the radar for clinicians of all specialties and types of practice.  

Continue reading